STAMPEDE: Docetaxel for Hormone-Naive Prostate Cancer
Christopher Sweeney, MBBS, reviews the updated STAMPEDE data presented the ESMO 2019 Annual Meeting.
Related Articles
Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC
The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.
ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC
Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Dr Asare on the Elevated Risk of Secondary Leukemias in PARP Inhibitors in Gynecologic Cancers
Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.
Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial
Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.
Zanidatamab in Previously-Treated HER2-Positive (HER2+) Biliary Tract Cancer (BTC): Overall Survival (OS) and Longer Follow-up From the Phase 2b HERIZON-BTC-01 Study
Zanidatamab is a HER2-targeted bispecific antibody that binds to two non-overlapping HER2 domains and crosslinks neighboring HER2 proteins. In the primary analysis of the phase…
Oxaliplatin Plus Fluoropyrimidine/Bevacizumab Does Not Improve Survival in Older Patients With mCRC
Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure
Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.
ASCO 2024 Applications in Gynecologic Oncology: Episode 2
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Osimertinib (osi) After Definitive Chemoradiotherapy (CRT) in Patients (pts) With Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA Study
The LAURA study (NCT03521154) evaluates the efficacy and safety of Osimertinib as a maintenance therapy following chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small…